These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30663942)

  • 1. Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury.
    Mak A; Uetrecht J
    J Immunotoxicol; 2019 Dec; 16(1):28-33. PubMed ID: 30663942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset.
    Metushi IG; Cai P; Dervovic D; Liu F; Lobach A; Nakagawa T; Uetrecht J
    J Immunotoxicol; 2015; 12(3):247-60. PubMed ID: 25046026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in PD1-/- Mice Cotreated with Anti-CTLA-4.
    Mak A; Uetrecht J
    Chem Res Toxicol; 2015 Aug; 28(8):1567-73. PubMed ID: 26154582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients.
    Metushi IG; Hayes MA; Uetrecht J
    Hepatology; 2015 Apr; 61(4):1332-42. PubMed ID: 25283142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury.
    Mak A; Uetrecht J
    J Immunotoxicol; 2015; 12(4):361-7. PubMed ID: 25425471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring an animal model of amodiaquine-induced liver injury in rats and mice.
    Liu F; Cai P; Metushi I; Li J; Nakayawa T; Vega L; Uetrecht J
    J Immunotoxicol; 2016 Sep; 13(5):694-712. PubMed ID: 27416278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Immune Modulators on Amodiaquine-Induced Liver Injury.
    Mak A; Cho TE; Uetrecht J
    Chem Res Toxicol; 2018 Aug; 31(8):739-744. PubMed ID: 29938495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury.
    Mak A; Cho T; Uetrecht J
    J Immunotoxicol; 2018 Dec; 15(1):90-95. PubMed ID: 29733743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury.
    Mak A; Johnston A; Uetrecht J
    J Immunotoxicol; 2017 Dec; 14(1):89-94. PubMed ID: 28279082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
    Mak A; Kato R; Weston K; Hayes A; Uetrecht J
    Toxicol Sci; 2018 Feb; 161(2):412-420. PubMed ID: 29087505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Injury Caused by Green Tea Extract in PD-1
    Cho T; Wang X; Yeung K; Cao Y; Uetrecht J
    Chem Res Toxicol; 2021 Mar; 34(3):849-856. PubMed ID: 33617238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.
    Baeck C; Wei X; Bartneck M; Fech V; Heymann F; Gassler N; Hittatiya K; Eulberg D; Luedde T; Trautwein C; Tacke F
    Hepatology; 2014 Mar; 59(3):1060-72. PubMed ID: 24481979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
    Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
    J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
    Schober A; Zernecke A; Liehn EA; von Hundelshausen P; Knarren S; Kuziel WA; Weber C
    Circ Res; 2004 Nov; 95(11):1125-33. PubMed ID: 15528472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges.
    Jee A; Sernoskie SC; Uetrecht J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury.
    Mak A; Uetrecht J
    Chem Res Toxicol; 2015 Dec; 28(12):2287-91. PubMed ID: 26529122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL2/CCR2-dependent recruitment of Th17 cells but not Tc17 cells to the lung in a murine asthma model.
    Wang A; Wang Z; Cao Y; Cheng S; Chen H; Bunjhoo H; Xie J; Wang C; Xu Y; Xiong W
    Int Arch Allergy Immunol; 2015; 166(1):52-62. PubMed ID: 25765592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL2 recruits T cells into the brain in a CCR2-independent manner.
    Cédile O; Wlodarczyk A; Owens T
    APMIS; 2017 Nov; 125(11):945-956. PubMed ID: 28836736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of CCL2 and CCR2 in host defense to coronavirus infection.
    Held KS; Chen BP; Kuziel WA; Rollins BJ; Lane TE
    Virology; 2004 Nov; 329(2):251-60. PubMed ID: 15518805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.